AcuraStem, Takeda Agree to License Agreement Focused on Advancing PIKfyve Therapeutics

Published on: 

Teams expected to collaborate on development and commercialization of multiple targets.

AcuraStem announced that it has officially inked a license agreement with Takeda to develop and commercialize its PIKfyve targeted therapeutics, including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of amyotrophic lateral sclerosis (ALS). A novel therapeutic target for ALS, PIKfyve may also be relevant for treating additional TDP-43 proteinopathies such as frontotemporal dementia (FTD).


Under the agreement, Takeda will receive an exclusive, worldwide license to the program while AcuraStem will receive an upfront and milestone payments totaling up to approximately $580 million if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement.

"Our mission at AcuraStem is to get our promising therapeutics to the patients who need them as quickly as possible," said Sam Alworth, MS, MBA, CEO, AcuraStem. "We are delighted to have secured a partner in Takeda who has the world class clinical development and commercial capabilities to deliver on our mission."

Reference: AcuraStem Enters into a License Agreement with Takeda to Advance PIKfyve Therapeutics. PR Newswire. September 25, 2023. Accessed September 26, 2023.